Stemtech (STEK) Cash from Investing Activities (2016 - 2017)

Stemtech's (STEK) quarterly Cash from Investing Activities came in at -$5000.0 in Q2 2017, up 4.69% quarter-over-quarter from -$5246.0 in Q4 2016.

Stemtech (STEK) Cash from Investing Activities (2016 - 2017) Analysis & Trends

Stemtech has disclosed Cash from Investing Activities across 2 years of filings, most recently posting -$5000.0 for Q2 2017.

Cash from Investing Activities for Q2 2017 came in at -$5000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was -$5000.0 (changed 0.0% YoY), and the FY2020 annual result was -$11599.0, changed N/A from the prior year.
Cash from Investing Activities came in at -$5000.0 for Q2 2017 at Stemtech, up from -$5246.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of -$5000.0 in Q2 2017 to a low of -$5246.0 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing (Qtr)
1	Teva Pharmaceutical Industries	38.77 Bn	35.04 Bn	1.97 Bn	229.00 Mn
2	Zoetis	34.11 Bn	32.16 Bn	1.62 Bn	-87.00 Mn
3	United Therapeutics	23.68 Bn	21.53 Bn	648.10 Mn	743.70 Mn
4	Aurora Cannabis	16.48 Bn	16.40 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.19 Bn	14.88 Bn	800.70 Mn	-506.20 Mn
6	Elanco Animal Health	11.44 Bn	11.01 Bn	785.00 Mn	-60.00 Mn
7	Alkermes	7.28 Bn	6.77 Bn	-116.06 Mn	-2.08 Bn
8	Lantheus Holdings	6.48 Bn	5.98 Bn	230.92 Mn	25.99 Mn
9	Hims & Hers Health	6.35 Bn	5.60 Bn	396.79 Mn	-15.45 Mn
10	Stemtech	-	-	354,677.00	-

Download Data